Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

How to access Pharma in Focus articles
  • If you're a current subscriber, See below

  • If you're new to Pharma in Focus, Click here

  • If you haven't SUBSCRIBED yet, Click here

Current Subscribers

If you are are current Full Text Subscriber or have taken out a Free Trial, please type your email address into the form below.

This will restore your access and return you to the Home Page.

Email Address
Open Forum
High marks for Australia's patent system
Lisa Haile partner at DLA Piper, talks about the latest developments in patents and how Australia's patent system has matured in the eyes of the world.
Pipeline Monitor
Europe fast-tracks new meds
Amgen's blood cancer treatment Kyprolis and BI's NOAC antidote Praxbind have been recommended under an accelerated procedure while Praluent has gained final EC approval.
Working Life
What's special about MSLs?
The use of medical science liaisons has grown fast in Australia over recent years. What is driving this growth and why has the role become so important to pharma? Team leaders give some answers.
Approvals Action
First competition for $40m Celgene drug
Apotex has registered the first generic competition for Celgene's blood cancer treatment Vidaza while two new HIV treatments have been approved by the TGA.
Special Report
Why MA Code complaints are waning
Complaints under the Medicines Australia Code appear to be in decline. Some say it's better compliance and improved inter-company dialogue but others say spikes can still be expected when rules change.
PBS Top 5
Gastroenterology: big brands and niche players
Big brands may dominate gastroenterology, but it is nonetheless a market which offers growth opportunities for more niche players.